• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Masimo Completes Sale of Consumer Audio Business to HARMAN International

    9/23/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email

    Masimo (NASDAQ:MASI) today announced it has completed the previously announced sale of its Sound United consumer audio business to HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd.

    Katie Szyman, Chief Executive Officer of Masimo, stated, "The completion of the Sound United sale is an important milestone in our ongoing efforts to focus on our core professional healthcare business. With this chapter behind us, we are even better positioned to broaden Masimo's patient impact, accelerate growth, and deliver stronger margins. We have exciting opportunities ahead, and I am confident that we will be able to continue building on our positive momentum to deliver value for all stakeholders. Finally, on behalf of the entire leadership team, I want to thank the Sound United team for their dedication and wish them continued success as part of HARMAN."

    With regard to the use of proceeds from the transaction, Masimo anticipates prioritizing share repurchases.

    Centerview Partners LLC and Morgan Stanley & Co. LLC served as financial advisors to Masimo and Sullivan & Cromwell LLP served as legal advisor to Masimo in connection with the transaction.

    @Masimo | #Masimo

    About Masimo

    Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, automation and connectivity solutions. Our mission is for Masimo innovations to empower clinicians to transform patient care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

    Forward-Looking Statements - Masimo

    This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding broadening our patient impact, accelerating growth, and delivering stronger margins, the anticipated use of funds from the transaction; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "on-going," "opportunity," "plan," "potential," "predicts," "forecast," "project," "seek," "should," "will," or "would," the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: our ability to execute on our business plans and achieve our financial and other goals; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at www.sec.gov. Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250922115110/en/

    Investor Contact:

    Eli Kammerman

    (949) 297-7077

    [email protected]

    Media Contact:

    Evan Lamb

    949-396-3376

    [email protected]

    Get the next $MASI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    11/8/2023Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HARMAN Completes Sound United Acquisition to Expand Premium Audio Leadership

    Strategic integration of Sound United's award-winning audio brands strengthens HARMAN's product portfolio and propels business growth HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, today announced it has completed the acquisition of Sound United, the former consumer audio business of Masimo Corporation (NASDAQ:MASI). Sound United's portfolio of iconic audio brands includes Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics. This press release features multimedia. View the full release here: https://www.busin

    9/23/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Completes Sale of Consumer Audio Business to HARMAN International

    Masimo (NASDAQ:MASI) today announced it has completed the previously announced sale of its Sound United consumer audio business to HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd. Katie Szyman, Chief Executive Officer of Masimo, stated, "The completion of the Sound United sale is an important milestone in our ongoing efforts to focus on our core professional healthcare business. With this chapter behind us, we are even better positioned to broaden Masimo's patient impact, accelerate growth, and deliver stronger margins. We have exciting opportunities ahead, and I am confident that we will be able to continue building on our positive momentum to d

    9/23/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs

    Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ:MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/Continuous Patient Monitoring with Masim

    9/17/25 8:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $437,940 worth of shares (3,000 units at $145.98), increasing direct ownership by 168% to 4,790 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/12/25 4:20:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James reiterated coverage on Masimo with a new price target

    Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

    12/27/24 7:29:29 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo upgraded by Raymond James with a new price target

    Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00

    11/6/24 7:17:22 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously

    6/3/24 7:31:43 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO, Consumer Division Tripodi Blair exercised 15,000 shares at a strike of $142.13 and covered exercise/tax liability with 8,078 shares, increasing direct ownership by 100% to 13,818 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    9/25/25 6:25:25 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Dadswell Charles

    4 - MASIMO CORP (0000937556) (Issuer)

    9/3/25 5:03:29 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Dadswell Charles

    3 - MASIMO CORP (0000937556) (Issuer)

    9/3/25 5:02:35 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    SEC Filings

    View All

    Masimo Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MASIMO CORP (0000937556) (Filer)

    9/29/25 4:18:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Corporation filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MASIMO CORP (0000937556) (Filer)

    9/23/25 9:02:14 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MASIMO CORP (0000937556) (Filer)

    8/19/25 4:48:07 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    View All

    Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

    American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

    7/8/25 8:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    $MASI
    Financials

    Live finance-specific insights

    View All

    HARMAN Completes Sound United Acquisition to Expand Premium Audio Leadership

    Strategic integration of Sound United's award-winning audio brands strengthens HARMAN's product portfolio and propels business growth HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, today announced it has completed the acquisition of Sound United, the former consumer audio business of Masimo Corporation (NASDAQ:MASI). Sound United's portfolio of iconic audio brands includes Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics. This press release features multimedia. View the full release here: https://www.busin

    9/23/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Reports Second Quarter 2025 Results

    Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371 million, representing 8% growth on a reported basis; Non-GAAP revenue of $370 million, representing 7% growth on a constant currency basis(2); GAAP net income per diluted share of $0.82; and Non-GAAP net income per diluted share(2) of $1.33, which grew 46% versus prior year period. Katie Szyman, Chief Executive Officer of Masimo, said, "We once again delivered strong results in the second quarter as our core health care business continued to demonstrate strong growth and earnings. W

    8/5/25 4:05:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered partic

    7/22/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    9/25/24 4:01:23 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    8/30/24 4:56:53 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    7/17/24 5:29:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care